Board certified rheumatologist Dr. Mahsa Tehrani discusses Novo Nordisk's decision to dramatically cut the U.S. list prices ...
Novo Nordisk announced Tuesday that it will cut U.S. list prices of Ozempic and Wegovy by up to 50% starting next year. The lower prices will take effect Jan. 1, 2027, the same time that reduced ...
Suffolk Construction is betting on the next wave of the Bay Area’s AI-driven growth — robotics and advanced manufacturing ...
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures ...
The popular weight loss drugs are both listed at more than $1,000 per month. The price cut is set for Jan. 1, 2027.
Feb 23 (Reuters) - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its ...
Evan Seigerman, managing director and head of healthcare research at BMO Capital Markets, joins BNN Bloomberg to discuss Novo Nordisk cutting medication prices.
The demos were real. The use cases were compelling. But the leap from "Claude can do this" to "enterprises will rip out ...
The prices of popular weight loss drugs Ozempic and Wegovy are to fall dramatically from next year, Danish drugmaker Novo Nordisk said Tuesday. The list price of Wegovy will be cu ...
The healthcare company said all doses will shift to a single monthly list price, cutting Wegovy’s price by about 50% and ...
Novo Nordisk (CSE:NOVOb) stock dropped 2.9% after JPMorgan downgraded the drugmaking giant to ‘neutral’ from ‘overweight’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results